Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation.

Makino A, Hasegawa T, Yamamoto T, Takagi H, Takahashi Y, Miyakoshi N, Amizuka N

Bone23 Feb 2024Cited by 7 (Europe PMC)

PMID38402920DOI10.1016/j.bone.2024.117056PepBankPUB-38402920

Publisher page PubMedAsk about this study

Summary

Osteoporotic vertebral fracture (OVF) is the most common type of osteoporotic fracture and is associated with immobility and mortality. Bone anabolic agents, such as abaloparatide (ABL), are usually administered to patients with OVF to prevent subsequent fractures. Although several studies have shown that bone anabolic agents promote healing of long bone fractures, there is little evidence of their healing effect on vertebral bone fractures. In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF. Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery. We found that ABL significantly increased bone mineral content and improved trabecular structural parameters at the vertebral defect site. Moreover, ABL significantly increased bone strength of the defected vertebrae. Bone histochemical analysis revealed formation of thick trabecular bone networks at the defect site after ABL administration, consistent with an improvement in trabecular structural parameters by ABL. ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site. On the other hand, ABL did not affect the number of cathepsin K-positive osteoclasts per bone surface, suggesting that ABL did not promote excessive bone resorption. Our findings suggest that ABL is useful not only for preventing secondary vertebral fractures but also for promoting bone healing in OVF.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats with vertebral defects, abaloparatide increased bone mineral content at the defect site.
In plain wordsIn rats with vertebral defects, abaloparatide increased bone mineral content at the injury.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone mineral content
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
We found that ABL significantly increased bone mineral content and improved trabecular structural parameters at the vertebral defect site.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292001
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats with vertebral defects, abaloparatide improved trabecular structural parameters at the defect site.
In plain wordsIn rats with vertebral defects, abaloparatide improved the structure of spongy bone at the injury.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedTrabecular structural parameters
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
We found that ABL significantly increased bone mineral content and improved trabecular structural parameters at the vertebral defect site.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292002
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats with vertebral defects, abaloparatide increased strength of the damaged vertebrae.
In plain wordsIn rats with vertebral defects, abaloparatide increased the strength of damaged vertebrae.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseVertebral bone strength
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
Moreover, ABL significantly increased bone strength of the defected vertebrae.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292003
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, thick trabecular bone networks formed at vertebral defect sites after abaloparatide administration.
In plain wordsIn rats, thick networks of spongy bone formed at vertebral defects after abaloparatide treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone network formation
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
Bone histochemical analysis revealed formation of thick trabecular bone networks at the defect site after ABL administration, consistent with an improvement in trabecular structural parameters by ABL.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292004
05AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats with vertebral defects, abaloparatide increased ALPase-positive osteoblastic cells.
In plain wordsIn rats with vertebral defects, abaloparatide increased bone-forming cells positive for ALPase.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseALPase-positive osteoblasts
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292005
06AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats with vertebral defects, abaloparatide increased PHOSPHO1-positive osteoblastic cells.
In plain wordsIn rats with vertebral defects, abaloparatide increased bone-forming cells positive for PHOSPHO1.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePHOSPHO1-positive osteoblasts
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292006
07AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats with vertebral defects, abaloparatide increased ALPase/PCNA double-positive cells.
In plain wordsIn rats with vertebral defects, abaloparatide increased cells positive for both ALPase and PCNA.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseALPase/PCNA double-positive cells
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292007
08AnimalAnimal study (in vivo)Mechanism
In ovariectomized rats with vertebral defects, abaloparatide did not change cathepsin K-positive osteoclast numbers per bone surface.
In plain wordsIn rats with vertebral defects, abaloparatide did not change cathepsin K-positive bone-resorbing cell numbers per bone surface.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeCathepsin K-positive osteoclasts
Study
ratn: not reported in source
Ovariectomized female Sprague-Dawley rats with vertebral drill-hole defects
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 μg/kg once daily · subcutaneous · up to 6 weeksAs given in this study (rat).
Source sentences
Summary
On the other hand, ABL did not affect the number of cathepsin K-positive osteoclasts per bone surface, suggesting that ABL did not promote excessive bone resorption.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF.
Summary · context
Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery.
Show in the study text Report a problemFND-3840292008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.